

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

**VOLUNTARY ANNOUNCEMENT
SHARE PURCHASE PURSUANT TO
THE 2021 H SHARE AWARD AND TRUST SCHEME**

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”, together with its subsidiary, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest developments of the Group.

Reference is made to the announcements of the Company dated August 30, 2021 and September 23, 2021 (the “**Announcements**”), and the circular dated September 7, 2021 (the “**Circular**”), in relation to the adoption of the 2021 H Share Award and Trust Scheme. Capitalized terms used herein shall have the same meanings as those defined in the Announcements and the Circular unless the context requires otherwise.

Since March 16, 2022 and up to the date of this announcement, the Trustee has purchased a total number of 1,363,500 Shares on the market at prices in the range of HKD10.84 to HKD13.76, pursuant to the 2021 H Share Award and Trust Scheme as a long-term equity incentive for employees in the future.

The Company may instruct the Trustee to make further purchases pursuant to the 2021 H Share Award and Trust Scheme and may make further announcements on the status of the 2021 H Share Award and Trust Scheme, including the number and price of the Shares purchased, from time to time.

The Share Purchase was funded by the Company's own financial resources other than proceeds from the listing of the Shares on the Main Board of the Stock Exchange. As at the date of this announcement, no Award under the 2021 H Share Award and Trust Scheme has been granted.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, April 13, 2022

As of the date of this announcement, the Board of the Company comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Hai Lu and Dr. Steven Dasong Wang as non-executive Directors, and Dr. Jian Ji., Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.